胰高血糖素样肽-1及类似物的降压作用研究进展

摘要/Abstract

摘要： 胰高血糖素样肽-1是体内一种重要的肠促胰岛素,具有葡萄糖浓度依赖性降糖作用,其类似物已用于2型糖尿病治疗。近年来的临床前和临床研究均发现胰高血糖素样肽-1及类似物有一定程度的降压作用,其作用机制可能与促进水钠排泄、改善血管内皮功能等有关。本文综述胰高血糖素样肽-1及类似物的降压作用。

关键词: 糖尿病, 胰高血糖素样肽-1, 血压, 机制

Abstract: Glucagon-like peptide-1 (GLP-1) is an incretine, which lowers blood glucose dependently on ambient glucose concentration, and its analogues have been used for treatment of type 2 diabetes mellitus. Recent findings including preclinical and clinical studies have demonstrated that GLP-1 and its analogues may have blood-pressure-lowering effect by inhibiting the proximal tubular sodium reabsorption and thereby increasing urinary excretion of sodium, or via an endothelium-independent mechanism.This review summarizes the recent findings regarding the antihypertensive effects of GLP-1 and its analogues.

Key words: Diabetes, Glucagon-like peptide-1, Blood pressure, Mechanism

中图分类号:

陈永飞, 邵华, 于锋. 胰高血糖素样肽-1及类似物的降压作用研究进展[J]. 中国临床药理学与治疗学, 2013, 18(2): 228-233.

CHEN Yong-fei, SHAO Hua, YU Feng. Research progress of glucagon-like peptide-1 and analogues on blood pressure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 228-233.

参考文献

[1] Shaw JE, Sicree RA, Zimmet PZ.Global estimates of the prevalence of diabetes for 2010 and 2030[J]. Diabetes Res Clin Pract, 2010,87(1): 4-14.
[2] Wild S, Roglic G, Green A, et al.Global prevalence of diabetes: estimates for the year 2000 and projections for 2030[J]. Diabetes Care, 2004,27(5): 1047-1053.
[3] Yang W, Lu J, Weng J, et al.Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010,362(12): 1090-1101.
[4] Adler AI, Stratton IM, Neil HW, et al.Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study[J]. BMJ, 2000,321(7258): 412-419.
[5] Group UKPDS.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38[J]. BMJ, 1998,317(7160): 703-713.
[6] Gerstein H.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy[J]. Lancet, 2000,355(9200): 253-259.
[7] Elrick H, Stimmler L, Hlad Jr C, et al.Plasma insulin response to oral and intravenous glucose administration[J]. J Clin Endocrinol Metab, 1964,24(10): 1076-1082.
[8] Mortensen K, Christensen LL, Holst JJ, et al.GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine[J]. Regul Pept, 2003,114(2): 189-196.
[9] Kang G, Chepurny OG, Rindler MJ, et al.A cAMP and Ca²+ coincidence detector in support of Ca²+-induced Ca²+ release in mouse pancreatic β cells[J]. J Physiol, 2005,566(1): 173-188.
[10] Baggio LL,Drucker DJ.Biology of incretins: GLP-1 and GIP[J]. Gastroenterology, 2007,132(6): 2131-2157.
[11] Yu M, Moreno C, Hoagland KM, et al.Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats[J]. J Hypertens, 2003,21(6): 1125-1135.
[12] Nystrõm T, Gonon AT, Sjöholm A, et al.Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism[J]. Regul Pept, 2005,125(1/2/3): 173-177.
[13] Gutzwiller JP, Tschopp S, Bock A, et al.Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men[J]. J Clin Endocrinol Metab, 2004,89(6): 3055-3061.
[14] Kim W,Egan JM.The role of incretins in glucose homeostasis and diabetes treatment[J]. Pharmacol Rev, 2008,60(4): 470-512.
[15] Agersø H, Jensen L, Elbrønd B, et al.The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men[J]. Diabetologia, 2002,45(2): 195-202.
[16] Laugero KD, Stonehouse AH, Guss S, et al.Exenatide improves hypertension in a rat model of the metabolic syndrome[J]. Metab Syndr Relat Disord, 2009,7(4): 327-334.
[17] Liu Q, Adams L, Broyde A, et al.The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats[J]. Cardiovasc Diabetol, 2010,9: 32.
[18] Hirata K, Kume S, Araki S, et al.Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model[J]. Biochem Biophys Res Commun, 2009,380(1): 44-49.
[19] Bullock B, Heller R, Habener J.Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor[J]. Endocrinology, 1996,137(7): 2968-2978.
[20] Barragan JM, Rodriguez RE, Eng J, et al.Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats[J]. Regul Pept, 1996,67(1): 63-68.
[21] Yamamoto H, Lee CE, Marcus JN, et al.Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons[J]. J Clin Invest, 2002,110(1): 43-52.
[22] Barragan J, Rodriguez R, Blazquez E.Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats[J]. Am J Physiol, 1994,266(3): E459-E466.
[23] Barragán JM, Eng J, Rodríguez R, et al.Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats[J]. Am J Physiol, 1999,277(5): E784-E791.
[24] Bojanowska E,Stempniak B.Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat[J]. Regul Pept, 2000,91(1/2/3): 75-81.
[25] Young AA.No effect of exendin-4 on blood pressure in man[J]. J Clin Invest,2002,Available from: No effect of exendin-4 on blood pressure in man[J]. J Clin Invest,2002,Available from: http://www.jci.org/eletters/view/15595.
[26] Golpon HA, Puechner A, Welte T, et al.Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat[J]. Regul Pept, 2001,102(2): 81-86.
[27] Ban K, Noyan-Ashraf MH, Hoefer J, et al.Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways[J]. Circulation, 2008,117(18): 2340-2350.
[28] Green BD, Hand KV, Dougan JE, et al.GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP[J]. Arch Biochem Biophys, 2008,478(2): 136-142.
[29] Blonde L, Klein EJ, Han J, et al.Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J]. Diabetes Obes Metab, 2006,8(4): 436-447.
[30] Okerson T, Yan P, Stonehouse A, et al.Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes[J]. Am J Hypertens, 2009,23(3): 334-339.
[31] Edwards CM, Todd JF, Ghatei MA, et al.Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects[J]. Clin Sci (Lond), 1998,95(6): 719-724.
[32] Toft-Nielsen M, Madsbad S, Holst JJ.Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients[J]. Diabetes Care, 1999,22(7): 1137-1143.
[33] De Vriese AS, Verbeuren TJ, Van De Voorde J, et al. Endothelial dysfunction in diabetes[J]. Br J Pharmacol, 2000,130(5): 963-974.
[34] Nystrõm T, Gutniak MK, Zhang Q, et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease[J]. Am J Physiol Endocrinol Metab, 2004,287(6): E1209-E1215.
[35] Marre M, Shaw J, Brändle M, et al.Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)[J]. Diabet Med, 2009,26(3): 268-278.
[36] Nauck M, Frid A, Hermansen K, et al.Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes[J]. Diabetes Care, 2009,32(1): 84-90.
[37] Garber A, Henry R, Ratner R, et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial[J]. Lancet, 2009,373(9662): 473-481.
[38] Zinman B, Gerich J, Buse JB, et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+ TZD)[J]. Diabetes Care, 2009,32(7): 1224-1230.
[39] Russell-Jones D, Vaag A, Schmitz O, et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial[J]. Diabetologia, 2009,52(10): 2046-2055.
[40] Buse JB, Rosenstock J, Sesti G, et al.Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)[J]. Lancet, 2009,374(9683): 39-47.
[41] Fonseca V, Falahati A, Zychma M, et al.A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure[J]. Diabetologia, 2009,52(Suppl 1): S299.
[42] Vilsbøll T, Christensen M, Junker AE, et al.Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials[J]. BMJ, 2012,344:d7771. doi: 10.1136/bmj.d7771. Review.
[43] Paul S, Best J, Klein K, et al.Effects of HbA(1c) and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide[J]. Diabetes Obes Metab, 2012,14(9):826-834.